Nair, H. K. R., Ayyo, A., et al. (2025)
A Quasi-experimental Study of Cellmax™ as an Adjuvant Therapy for Individuals with Chronic Wounds

  • Study Design: Quasi-experimental, clinical investigation
  • CIP Reference: CELLMAX-23-1.6
  • Ethics Reference: NMRR ID-23-00821-PEC
  • MDA Notification: MDA/CIU/2024/6370
  • Patient Cohort: 88 subjects with complex wounds (DFUs, lymphovascular & traumatic wounds)

Key Results:

  • 44,3% complete wound closure (39 patients), 100% epithelialization
  • Average time-to-closure: 54 days
  • 45% of patients achieved ≥50% wound area reduction
  • Progression visible from 4th week after treatment
  • Zero adverse events

Publications:

  1. Wounds Asia 2022 | Vol 5 Issue 3 — “Clinical effect of subcutaneous application of Cellmax™ on treating chronic wounds: a case series”
  2. Nair et al. (2025) — Full clinical investigation report.

 

Regulatory Information:

Product

MDA Registration

MDA License

Cellmax™ Wound Spray

GD4607326-239804

MDA-4519-K123

Cellmax™ Freeze Dried Powder

GD8996426-239437

MDA-4519-K123

 

Manufacturer: Era Health Care Sdn. Bhd. (1155421-T)
5, Persiaran Industri Bercham 10, Kawasan Perindustrian Ringan Bercham, 31400 Ipoh, Perak

Quality Standards:

  • ISO 13485 compliant
  • GDPMD compliant
  • Biocompatibility tested under ISO 10993 (non-irritant, non-sensitizing)

Hospital Kuala Lumpur, Malaysia

Wound Care Unit, Department of Internal Medicine, Hospital Kuala Lumpur Malaysia.

Cellmax™ is now actively being used to conduct clinical studies in the Wound Care Unit, Department of Internal Medicine, Hospital Kuala Lumpur, Malaysia. The clinical case studies aim to investigate the recovery of chronic wounds treated with Cellmax™ based on standard debridement procedure for wound healing and application of subcutaneous injection of Cellmax™ as first-line therapy.

We are proud to share that the first part of the clinical studies had been published in Wounds Asia 2022.

Dedikasi ABA Bioscience

Pharmaceutical & Skincare Research Technology Park Malaysia, Kuala Lumpur Malaysia.

DEDIKASI ABA BIOSCIENCES is a cosmeceutical Research & Development (R&D) laboratory located at Biotechnology Incubation Centre, Technology Park Malaysia (TPM), Bukit Jalil Kuala Lumpur, Malaysia. The R&D laboratory is lead by a dedicated team of pharmaceutical consultant, senior development chemists and research scientists, with years of research experience in this segment. The research team emphasizes on high value innovation, advanced research and scientific excellence.

They focused on mesenchymal stem cell (MSCs) secretome research and its clinical application, and the use of more naturally derived and high-grade cosmeceutical ingredients. They explore development of innovative formulation with MSC secretome and incorporate them into new high-end cosmetic products.